Te Liu, Jiajia Lin, Chuan Chen, Xiaoli Nie, Fangfang Dou, Jiulin Chen, Zhenxin Wang, Zhangbin Gong.Thymopentin alleviates premature ovarian failure in mice by activating YY2/Lin28A and inhibiting the expression of let‐7 family microRNAs. Te Liu, Fangyuan Jing, Peirong Huang, Zixiang Geng, Jianghong Xu, Jiahui Li, Danping Chen, Ying Zhu, Zhenxin Wang, Willian Huang, Chuan Chen.International Journal of Pharmaceutics 2021, 605, 120807. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up. Maria Camilla Operti, Alexander Bernhardt, Silko Grimm, Andrea Engel, Carl Gustav Figdor, Oya Tagit.FRET Ratiometric Nanoprobes for Nanoparticle Monitoring. Guangze Yang, Yun Liu, Jisi Teng, Chun-Xia Zhao.Highly efficient fluorescence resonance energy transfer in co-encapsulated BODIPY nanoparticles. Priyadarshine Hewavitharanage, Launa Steele, Isaac Dickenson.A molecular dyad delivered by biodegradable polymeric nanoparticles for combined PDT and NO-PDT in cancer cells. Graziano, Aurore Fraix, Claudia Conte, Fabiana Quaglia, Salvatore Sortino.
This article is cited by 14 publications. The results of this study expand our knowledge on drug release and degradation behavior of PLGA nanoparticles under different physiological conditions, which will prove useful for the rational design of PLGA-based formulations for various applications that can be translated into clinical practice. PLGA nanoparticles systemically administered to mice predominantly accumulate in the liver, in which FRET no longer takes place at time points as early as 24 h postadministration as determined by ex vivo organ imaging and flow cytometry analysis. Accordingly, PLGA nanoparticles are colloidally stable for more than 2 weeks when incubated in aqueous buffers in situ, whereas in vitro particle degradation starts in between 24 and 48 h, reaching a complete loss of FRET at 72 h as shown with fluorescence microscopy imaging and flow cytometry analysis. The stability of PLGA nanoparticles is studied via monitoring the variations of fluorescence emission characteristics along with colloidal characterization. Here, we present the FRET-based stability assessment of poly(lactic- co-glycolic acid) (PLGA) nanoparticles encapsulating BODIPY-FL12 and Nile Red as the donor and acceptor, respectively. Förster resonance energy transfer (FRET)-based fluorescence labeling approaches are promising tools to study nanoparticle stability under different physiological conditions. The knowledge of in vitro and in vivo stability of polymeric nanoparticles is vital for the development of clinical formulations for drug delivery and cell labeling applications.
0 kommentar(er)
